Ann: Key Day 100 Survival Results In P3 GvHD Trial, page-89

@roka

Re "This is a product already approved in several markets, so the results are to be expected"

I think you are drawing a reasonable conclusion. The market has long known about the previous success in other regions with the treatment of agvhd in children. It is also aware (or should be) of the size of the child market, and the fact that mesoblast have publicly stated it only works in a 40% subset of adults.

At a market cap well above $700 million with only a trickle of news coming in regarding partners for tier 1 treatments, I'd imagine many potential investors are happy to watch what happens.